James Jorgenson, MS, RPh, FASHP

With continued increases in the US drug spend, the evolution of fully transparent PBM programs has introduced an alternative approach to traditional PBM structures aimed at enhanced utilization and cost control.

Strategies for controlling use of specialty pharmaceuticals should focus on situations where these agents are used inappropriately and on improvement of the complex billing process.

While studies have identified multiple causes for medication nonadherence, interventions have been largely unsuccessful. Opportunity exists to improve adherence and positively impact healthcare quality and costs.